=> file caplus
FILE 'CAPLUS' ENTERED AT 13:13:56 ON 08 DEC 2009

FILE COVERS 1907 - 8 Dec 2009 VOL 151 ISS 24
FILE LAST UPDATED: 7 Dec 2009 (20091207/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 115 SEA FILE=REGISTRY SSS FUL L1
L4 10 SEA FILE=CAPLUS L3

=> d l4 1-10 ibib abs hitstr

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:855540 CAPLUS
DOCUMENT NUMBER: 151:173252
TITLE: Preparation of 2- and 3-substituted 5,6-diarylpyridines as CB1 cannabinoid receptor antagonists

INVENTOR(S): Barre, Lionel; Congy, Christian; Pointeau, Philippe; Rinaldi-Carmona, Murielle
PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.
SOURCE: PCT Int. Appl., 81pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009087285	A1	20090716	WO 2008-FR1421	20081010
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
FR 2922209	A1	20090417	FR 2007-7186	20071012

PRIORITY APPLN. INFO.: FR 2007-7186 A 20071012
OTHER SOURCE(S): MARPAT 151:173252
GI



I



II

AB Title compds. I [Q = O, S, NR1; R1 = H, alkyl; Z = NR3XR4, NR3COOR5, OCONR3R5; X = CO, SO2, CONR6, CSNR6; R3, R6 = independently H, alkyl; R4 = (un)substituted alkyl, Ph, indolyl, etc.; R5 = (un)substituted phenyl; Ar1, Ar2 = independently (un)substituted phenyl; Y = CN, (un)substituted phenoxy, alkoxycarbonyl, alkylsulfonyl, CONH2 and derivs., etc.; A = (CH2)n; n = 0-1; B = (Alk')m; Alk' = linear or branched C1-5 alkyl; m = 0-1; their free bases and their addition salts] were prepared as antagonists of CB1 cannabinoid receptors (no data) and for treatment of the diseases it implies (no data). Thus, a multi-step synthesis starting from [6-(4-bromophenyl)-5-(2,4-dichlorophenyl)-2-(methoxymethyl)pyridin-3-yl]methanol was given for diphenylpyridine II. I exhibited an excellent affinity in vitro (IC50 ≤ 5•10-7 M) for the CB1 cannabinoid receptors. The antagonist nature of compds. I was demonstrated by adenylate-cyclase inhibition models, and toxicity was compatible with therapeutic use (no data). The interaction of I with the brain CB1 receptors was determined using a test of ex vivo binding of [3H]-CP55940 after i.v. injection to mice (no data). The interaction of I with the peripheral CB1 receptors was determined using a test of reversion of the inhibiting effect of CP55940 on gastrointestinal transit after oral administration to mice (no data). Thus, I are useful for treating psychiatric, metabolic, and gastrointestinal disorders, drug dependence, etc. (no data).

IT 1173144-25-6P, N-[[6-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-3-[[[(2-fluorobenzyl)carbamoyl]amino]methyl]pyridin-2-yl]methyl]-2-hydroxyacetamide 1173144-28-9P, N-[[6-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-[[(hydroxyacetyl)amino]methyl]pyridin-3-yl]methyl]-4-(trifluoromethyl)benzamide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of diphenylpyridines as antagonists of CB1 cannabinoid receptors)

RN 1173144-25-6 CAPLUS

CN Acetamide, N-[[6-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-3-[[[[[(2-fluorophenyl)methyl]amino]carbonyl]amino]methyl]-2-pyridinyl]methyl]-2-hydroxy- (CA INDEX NAME)



RN 1173144-28-9 CAPLUS

CN Benzamide, N-[[6-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



IT 1143624-05-8P 1143625-17-5P,
N-[[6-(4-Bromophenyl)-5-(2,4-dichlorophenyl)-2-
[[(hydroxyacetyl)amino]methyl]pyridin-3-yl]methyl]-4-
[(trifluoromethyl)thio]benzamide 1173144-12-1P
1173144-13-2P 1173144-14-3P 1173144-31-4P,
N-[[6-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-
[[(hydroxyacetyl)amino]methyl]pyridin-3-yl]methyl]-4-
[(trifluoromethyl)thio]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of diphenylpyridines as antagonists of CB1 cannabinoid receptors)

RN 1143624-05-8 CAPLUS
CN Benzamide, N-[[6-(4-bromophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-[(trifluoromethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 1143625-17-5 CAPLUS
CN Benzamide, N-[[6-(4-bromophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-[(trifluoromethyl)thio]- (CA INDEX NAME)



RN 1173144-12-1 CAPLUS
CN Benzamide, N-[[6-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-[(trifluoromethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)



RN 1173144-13-2 CAPLUS
CN Acetamide, N-[[6-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-3-[[[[[(2-fluorophenyl)methyl]amino]carbonyl]amino]methyl]-2-pyridinyl]methyl]-2-hydroxy-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 1173144-14-3 CAPLUS
CN Benzamide, N-[[6-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 1173144-31-4 CAPLUS
CN Benzamide, N-[[6-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-[(trifluoromethyl)thio]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:457259 CAPLUS
DOCUMENT NUMBER: 150:447705
TITLE: Preparation of 2- and 3-substituted 5,6-diarylpyridines as CB1 cannabinoid receptor antagonists
INVENTOR(S): Barre, Lionel; Congy, Christian; Pointeau, Philippe; Rinaldi, Carmona Murielle
PATENT ASSIGNEE(S): Sanofi Aventis, Fr.
SOURCE: Fr. Demande, 66pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2922209	A1	20090417	FR 2007-7186	20071012
WO 2009087285	A1	20090716	WO 2008-FR1421	20081010

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: FR 2007-7186 A 20071012
OTHER SOURCE(S): MARPAT 150:447705
GI



I



II

AB Title compds. I [Q = O, S, NR1; R1 = H, alkyl; Z = NR3XR4, NR3COOR5, OCONR3R5; X = CO, SO2, CONR6, CSNR6; R3, R6 = independently H, alkyl; R4 = (un)substituted alkyl, Ph, indolyl, etc.; R5 = (un)substituted phenyl; Ar1, Ar2 = independently (un)substituted phenyl; Y = CN, (un)substituted phenoxy, alkoxycarbonyl, alkylsulfonyl, CONH2 and derivs., etc.; A = (CH2)n; n = 0-1; B = (Alk')m; Alk' = linear or branched C1-5 alkyl; m = 0-1; their free bases and their addition salts, and their hydrates and solvates] were prepared as antagonists of CB1 cannabinoid receptors (no data) and for treatment of the diseases it implies (no data). Thus, a multi-step synthesis starting from [6-(4-bromophenyl)-5-(2,4-dichlorophenyl)-2-(methoxymethyl)pyridin-3-yl]methanol was given for diphenylpyridine II. I exhibited an excellent affinity in vitro (IC50 ≤ 5•10-7 M) for the CB1 cannabinoid receptors. The antagonist nature of compds. I was demonstrated by adenylate-cyclase inhibition models, and toxicity was compatible with therapeutic use (no data). The interaction of I with the brain CB1 receptors was determined using a test of ex vivo binding of [3H]-CP55940 after i.v. injection to mice (no data). The interaction of I with the peripheral CB1 receptors was determined using a test of reversion of the inhibiting effect of CP55940 on gastrointestinal transit after oral administration to mice (no data). Thus, I are useful for treating psychiatric, metabolic, and gastrointestinal disorders, smoking cessation, etc. (no data).

IT 1143624-05-8P 1143625-17-5P,
N-[[6-(4-Bromophenyl)-5-(2,4-dichlorophenyl)-2-[(2-hydroxyacetylamino)methyl]pyridin-3-yl]methyl]-4-[(trifluoromethyl)thio]benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of diphenylpyridines as antagonists of CB1 cannabinoid receptors)

RN 1143624-05-8 CAPLUS
CN Benzamide, N-[[6-(4-bromophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-[(trifluoromethyl)thio]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 1143625-17-5 CAPLUS
CN Benzamide, N-[[6-(4-bromophenyl)-5-(2,4-dichlorophenyl)-2-[[(2-hydroxyacetyl)amino]methyl]-3-pyridinyl]methyl]-4-[(trifluoromethyl)thio]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:276997 CAPLUS
DOCUMENT NUMBER: 150:447822
TITLE: Process Development of a Potent Bradykinin 1 Antagonist
AUTHOR(S): Menzel, Karsten; Machrouhi, Fouzia; Bodenstein, Matthew; Alorati, Anthony; Cowden, Cameron; Gibson, Andrew W.; Bishop, Brian; Ikemoto, Norihiro; Nelson, Todd D.; Kress, Michael H.; Frantz, Doug E.

CORPORATE SOURCE: Merck Research Laboratories, Department of Process Research, Merck and Co. Inc., Wayne, PA, 19087, USA
SOURCE: Organic Process Research & Development (2009), 13(3), 519-524
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB As part of Merck's continued research effort on inflammation and pain, a safe synthesis of an orally bioavailable and CNS penetrant bradykinin 1 antagonist was developed and demonstrated on kilogram scale. The key step included a novel regioselective metal-halogen exchange reaction on 1,2-dibromo-5-chloro-3-fluorobenzene using isopropylmagnesium chloride to install the 1,2,4-oxadiazole ring structure. Suzuki cross-coupling reaction between a highly functionalized and sterically hindered electrophile and boronic ester generated the biaryl ring system, which was converted to the target mol. (I) using standard chemical The safe installation of a 1,2,4-oxadiazole ring proved to be challenging since the original synthetic route relied on the preparation of a highly functionalized benzonitrile using potassium cyanide and resulted in low yields and large amts. of potentially hazardous waste. Overall, a safe and robust synthesis was developed, which occurred in eight linear steps with an overall yield of 28%.

IT 858412-39-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of a Bradykinin 1 antagonist in a safe and robust manner over eight linear steps)

RN 858412-39-2 CAPLUS

CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1472960 CAPLUS
DOCUMENT NUMBER: 150:159291
TITLE: Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies
AUTHOR(S): Tiller, Philip R.; Yu, Sean; Bateman, Kevin P.; Castro-Perez, Jose; McIntosh, Ian S.; Kuo, Yushin; Baillie, Thomas A.
CORPORATE SOURCE: Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Rapid Communications in Mass Spectrometry (2008), 22(22), 3510-3516
CODEN: RCMSEF; ISSN: 0951-4198
PUBLISHER: John Wiley & Sons Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Recent changes in the regulatory environment have led to a need for new methods to assess circulating human drug metabolites in early clin. studies with respect to their potential toxicol. impact. The specific goals of such studies are to determine if the metabolites present in human plasma following administration of a drug candidate also are observed in plasma from the animal studies employed for preclin. toxicol. evaluation, and to estimate corresponding exposure margins (animal:human) for the major metabolites. Until recently, the accepted best practice for the characterization of circulating drug metabolites utilized liquid chromatog./tandem mass spectrometry (LC/MS/MS)-based methodologies, in conjunction with authentic chemical stds., for the detection and quant. analyses of metabolites predicted from both animal studies and expts. with human liver prepns. in vitro. While this approach is satisfactory for anticipated biotransformation products, metabolites that were not expected to circulate in human plasma frequently escape detection. Current accurate mass instruments enable the use of the technique of fractional mass filtering to detect both expected and unexpected metabolites in a rapid, less resource-intensive and more robust manner. Application of this technol. to several clin. development programs at Merck Research Labs. has demonstrated the value of fractional mass filtering in the assessment of circulating drug metabolites in early clin. trials.

IT 858412-39-2
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; fractional mass filtering as a means to assess circulating metabolites in early human clin. studies)
RN 858412-39-2 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1136067 CAPLUS
DOCUMENT NUMBER: 149:534142
TITLE: Bradykinin B1 receptor antagonists: An α-hydroxy amide with an improved metabolism profile
AUTHOR(S): Kuduk, Scott D.; Chang, Ronald K.; DiPardo, Robert M.; Di Marco, Christina N.; Murphy, Kathy L.; Ransom, Richard W.; Reiss, Duane R.; Tang, Cuyue; Prueksaritanont, Thomayant; Pettibone, Douglas J.; Bock, Mark G.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(18), 5107-5110
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 149:534142
GI



I

AB A series of carbo- and heterocyclic α-hydroxy amide-derived bradykinin B1 antagonists, e.g., I, was prepared and evaluated. A 4,4-difluorocyclohexyl α-hydroxy amide was incorporated along with a 2-Me tetrazole in lieu of an oxadiazole to afford a suitable compound with good pharmacokinetic properties, CNS penetration, and clearance by multiple metabolic pathways.

IT 858412-39-2
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(preparation, bradykinin B1 receptor binding affinities, P-glycoprotein transport properties, and pharmacokinetics of α-hydroxy amides incorporating a Me tetrazole substituent)

RN 858412-39-2 CAPLUS

CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:85173 CAPLUS
DOCUMENT NUMBER: 148:369250
TITLE: α-Hydroxy amides as a novel class of bradykinin B1 selective antagonists
AUTHOR(S): Wood, Michael R.; Schirripa, Kathy M.; Kim, June J.; Kuduk, Scott D.; Chang, Ronald K.; Di Marco, Christina N.; DiPardo, Robert M.; Wan, Bang-Lin; Murphy, Kathy L.; Ransom, Richard W.; Chang, Raymond S. L.; Holahan, Marie A.; Cook, Jacquelynn J.; Lemaire, Wei; Mosser, Scott D.; Bednar, Rodney A.; Tang, Cuyue; Prueksaritanont, Thomayant; Wallace, Audrey A.; Mei, Qin; Yu, Jian; Bohn, Dennis L.; Clayton, Frank C.; Adarayn, Emily D.; Sitko, Gary R.; Leonard, Yvonne M.; Freidinger, Roger M.; Pettibone, Douglas J.; Bock, Mark G.
CORPORATE SOURCE: Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(2), 716-720
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Antagonism of the bradykinin B1 receptor represents a potential treatment for chronic pain and inflammation. Novel antagonists incorporating α-hydroxy amides were designed that display low-nanomolar affinity for the human bradykinin B1 receptor and good bioavailability in the rat and dog. In addition, these functionally active compds. show high passive permeability and low susceptibility to phosphoglycoprotein mediated efflux, predictive of good CNS exposure.
IT 858412-39-2 858412-99-4 858413-47-5
858413-50-0 858413-57-7 858413-64-6
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(α-hydroxy amides as bradykinin B1 antagonists)
RN 858412-39-2 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858412-99-4 CAPLUS
CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-47-5 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-50-0 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-57-7 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-64-6 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:793702 CAPLUS
DOCUMENT NUMBER: 147:166197
TITLE: Preparation of tartaric acid functional compounds for the treatment of disorders mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE and TNF-α
INVENTOR(S): Siddiqui, M. Arshad; Mansoor, Umar Faruk; Reddy, Panduranga Adulla P.; Madison, Vincent S.
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 556pp., Cont.-in-part of U.S. Ser. No. 291,595.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20070167426	A1	20070719	US 2006-599784		20061115
US 20060252778	A1	20061109	US 2005-142601		20050601
US 20060178366	A1	20060810	US 2005-291595		20051201
PRIORITY APPLN. INFO.:			US 2004-576153P	P	20040602
			US 2005-142601	A2	20050601
			US 2005-291595	A2	20051201

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 147:166197
GI



I



II

AB The title compds. I [A = (un)substituted benzimidazol-2-yl, imidazol-2-yl, CONH2, CSNH2, etc.; J, E = O, S, NR5 (wherein R5 = H, alkyl, alkylaryl); T = O, S; R10, R20 = H, alkyl, fluoroalkyl; R30 = H, alkyl or R30 and R40, taken together with N to which R40 is attached, are joined to form 4-7 membered (un)substituted heterocyclyl; R40, R50 = H, alkyl; W = [C(R13)2]n (wherein n = 0-5 or a bond; R13 = H, halo, OH, etc.); X = a bond, alkyl, cycloalkyl, etc.; Y = a bond, O, S, NH, etc.; Z = H, alkyl, aryl, etc.; or their pharmaceutically acceptable salts] which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE and TNF-α, were prepared E.g., a multi-step synthesis of II, starting from 2,2-dimethyl-[1,3]dioxolane-4R,5R-dicarboxylic acid monomethyl ester and 2-(thien-1-yl)ethylamine, was given. The compds. I were tested against LpxC and ADMP (biol. data given for representative compds. I).

IT 871713-82-5P 871713-83-6P 871713-84-7P
871713-85-8P 871713-88-1P 871713-89-2P

871713-90-5P 871713-91-6P 871713-92-7P
871713-93-8P 871713-94-9P 871713-95-0P
871713-96-1P 871723-96-5P 871723-99-8P
871724-02-6P 871724-05-9P 871728-75-5P
871728-76-6P 871728-77-7P 871728-78-8P
871728-79-9P 871728-80-2P 871729-25-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tartaric acid functional compds. for treating inflammation, microbial infection, and other disorders mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE and TNF-α)

RN 871713-82-5 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-chlorophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-83-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[(5-phenyl-2-pyridinyl)methyl]-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-84-7 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-(2-methoxyphenyl)-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-85-8 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-88-1 CAPLUS
CN 2H-Isoindole-2-butanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-1,3-dihydro-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-89-2 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-90-5 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-2-(2-thiazolyl)-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-91-6 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-2-(4-fluorophenyl)-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-92-7 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-ethoxyphenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-93-8 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-[2-(1-methylethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-94-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[[5-[2-(phenylmethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-95-0 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-96-1 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-(2-methoxyphenyl)-2-pyridinyl]methyl]-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871723-96-5 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[1-[5-(2-cyanophenyl)-2-pyridinyl]ethyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871723-99-8 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[1-[5-[2-(aminocarbonyl)phenyl]-2-pyridinyl]ethyl]-2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871724-02-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[1-[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]ethyl]-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871724-05-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[1-[5-(2-ethoxyphenyl)-2-pyridinyl]ethyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-75-5 CAPLUS
CN 2H-Isoindole-2-butanamide, N-[[6-cyano-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-1,3-dihydro-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-76-6 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-N-[[6-methoxy-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-77-7 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-N-[[1-oxido-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-78-8 CAPLUS
CN 2H-Isoindole-2-butanamide, 1,3-dihydro-α,β-dihydroxy-N-[[1-oxido-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-79-9 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-ethoxy-4-fluorophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-80-2 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-γ-oxo-N-[[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871729-25-8 CAPLUS
CN 2-Pyridinepropanamide, α,β-dihydroxy-N-[[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:796760 CAPLUS
DOCUMENT NUMBER: 145:230531
TITLE: Preparation of tartaric acid functional compounds for the treatment of inflammatory disorders mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE and TNF-α
INVENTOR(S): Siddiqui, M. Arshad; Mansoor, Umar Faruk; Reddy, Panduranga A.; Madison, Vincent S.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 523 pp., Cont.-in-part of U.S. Ser. No. 142,601.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060178366	A1	20060810	US 2005-291595	20051201
US 20060252778	A1	20061109	US 2005-142601	20050601
US 20070167426	A1	20070719	US 2006-599784	20061115
AU 2006320621	A1	20070607	AU 2006-320621	20061129
CA 2632922	A1	20070607	CA 2006-2632922	20061129
WO 2007064749	A1	20070607	WO 2006-US45773	20061129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1957058	A1	20080820	EP 2006-844652	20061129
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009518294	T	20090507	JP 2008-543439	20061129
MX 2008007092	A	20080814	MX 2008-7092	20080602

KR 2008071200	A	20080801	KR 2008-715687		20080627
CN 101426486	A	20090506	CN 2006-80052101		20080730
PRIORITY APPLN. INFO.:			US 2004-576153P	P	20040602
			US 2005-142601	A2	20050601
			US 2005-291595	A2	20051201
			WO 2006-US45773	W	20061129

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 145:230531

GI



I



II

AB The title compds. I [A = (un)substituted benzimidazol-2-yl, imidazol-2-yl, CONH2, CSNH2, etc.; J, E = O, S, NR5 (wherein R5 = H, alkyl, alkylaryl); T = O, S; R10, R20 = H, alkyl, fluoroalkyl; R30 = H, alkyl or R30 and R40, taken together with N to which R40 is attached, are joined to form 4-7 membered (un)substituted heterocyclyl; R40, R50 = H, alkyl; W = [C(R13)2]n (wherein n = 0-5 or a bond; R13 = H, halo, OH, etc.); X = a bond, alkyl, cycloalkyl, etc.; Y = a bond, O, S, NH, etc.; Z = H, alkyl, aryl, etc.; or their pharmaceutically acceptable salts] which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE and TNF-α, were prepared E.g., a multi-step synthesis of II, starting from 2,2-dimethyl-[1,3]dioxolane-4R,5R-dicarboxylic acid monomethyl ester and 2-(thien-1-yl)ethylamine, was given. The compds. I were tested against LpxC and ADMP (biol. data given for representative compds. I).

IT 871713-82-5P 871713-83-6P 871713-84-7P
871713-85-8P 871713-88-1P 871713-89-2P
871713-90-5P 871713-91-6P 871713-92-7P
871713-93-8P 871713-94-9P 871713-95-0P
871713-96-1P 871723-96-5P 871723-99-8P
871724-02-6P 871724-05-9P 871728-75-5P
871728-76-6P 871728-77-7P 871728-78-8P
871728-79-9P 871728-80-2P 871729-25-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of tartaric acid functional compds. for treating inflammatory disorders mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE and TNF-α)

RN 871713-82-5 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-chlorophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-83-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[(5-phenyl-2-pyridinyl)methyl]-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-84-7 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-(2-methoxyphenyl)-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-85-8 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-88-1 CAPLUS
CN 2H-Isoindole-2-butanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-1,3-dihydro-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-89-2 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-90-5 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-2-(2-thiazolyl)-,

(αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-91-6 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-2-(4-fluorophenyl)-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-92-7 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-ethoxyphenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-93-8 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-[2-(1-methylethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-94-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[[5-[2-(phenylmethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-95-0 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-96-1 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-(2-methoxyphenyl)-2-pyridinyl]methyl]-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871723-96-5 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[1-[5-(2-cyanophenyl)-2-pyridinyl]ethyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871723-99-8 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[1-[5-[2-(aminocarbonyl)phenyl]-2-pyridinyl]ethyl]-2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871724-02-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[1-[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]ethyl]-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871724-05-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[1-[5-(2-ethoxyphenyl)-2-pyridinyl]ethyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-75-5 CAPLUS
CN 2H-Isoindole-2-butanamide, N-[[6-cyano-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-1,3-dihydro-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-76-6 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-N-[[6-methoxy-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-77-7 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-N-[[1-oxido-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-78-8 CAPLUS
CN 2H-Isoindole-2-butanamide, 1,3-dihydro-α,β-dihydroxy-N-[[1-oxido-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-79-9 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-ethoxy-4-fluorophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-80-2 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-γ-oxo-N-[[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871729-25-8 CAPLUS
CN 2-Pyridinepropanamide, α,β-dihydroxy-N-[[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1331127 CAPLUS
DOCUMENT NUMBER: 144:69727
TITLE: Preparation of tartaric acid functional compounds for the treatment of inflammatory disorders
INVENTOR(S): Guo, Zhuyan; Orth, Peter; Zhu, Zhaoning; Mazzola,

Robert D.; Chan, Tin Yau; Vaccaro, Henry A.; McKittrick, Brian; Kozlowski, Joseph A.; Lavey, Brian J.; Zhou, Guowei; Paliwal, Sunil; Wong, Shing-Chun; Shih, Neng-Yang; Ting, Pauline C.; Rosner, Kristin E.; Shipps, Gerald W., Jr.; Siddiqui, M. Arshad; Belanger, David B.; Dai, Chaoyang; Li, Dansu; Girijavallabhan, Vinay M.; Popovici-Muller, Janeta; Yu, Wensheng; Zhao, Lianyun
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 889 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121130	A2	20051222	WO 2005-US19131	20050601
WO 2005121130	A3	20060720		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005252201	A1	20051222	AU 2005-252201	20050601
CA 2569111	A1	20051222	CA 2005-2569111	20050601
EP 1773821	A2	20070418	EP 2005-759261	20050601
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101027295	A	20070829	CN 2005-80026189	20050601
JP 2008501691	T	20080124	JP 2007-515501	20050601
MX 2006014054	A	20070131	MX 2006-14054	20061130
ZA 2006010055	A	20090527	ZA 2006-10055	20061130
IN 2006CN04431	A	20070629	IN 2006-CN4431	20061201
KR 2007103671	A	20071024	KR 2006-726812	20061220

PRIORITY APPLN. INFO.:	US 2004-576153P	P	20040602
	WO 2005-US19131	W	20050601

OTHER SOURCE(S): CASREACT 144:69727; MARPAT 144:69727
GI



I



II

AB The title compds. I [A = (un)substituted benzimidazol-2-yl, imidazol-2-yl, CONH2, CSNH2; J, E = O, S, NR5 (wherein R5 = H, alkyl, alkylaryl); T = O, S; R10, R20 = H, alkyl, fluoroalkyl; R30 = H, alkyl or R30 and R40, taken together with N to which R40 is attached, are joined to form 4-7 membered (un)substituted heterocyclyl; R40, R50 = H, alkyl; W = [C(R13)2]n (wherein n = 0-5; R13 = H, halo, OH, etc.); X = a bond, alkyl, cycloalkyl, etc.; Y = a bond, O, S, NH, etc.; Z = H, alkyl, aryl, etc.; or their pharmaceutically acceptable salts] which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-α or combinations thereof, were prepared E.g., a multi-step synthesis of II, starting from 2,2-dimethyl-[1,3]dioxolane-4R,5R-dicarboxylic acid monomethyl ester and 2-(thien-1-yl)ethylamine, was given. The compds. I were tested against TACE (biol. data given for representative compds. I).

IT 871713-82-5P 871713-83-6P 871713-84-7P
871713-85-8P 871713-88-1P 871713-89-2P
871713-90-5P 871713-91-6P 871713-92-7P
871713-93-8P 871713-94-9P 871713-95-0P
871713-96-1P 871723-96-5P 871723-99-8P
871724-02-6P 871724-05-9P 871728-75-5P
871728-76-6P 871728-77-7P 871728-78-8P
871728-79-9P 871728-80-2P 871729-25-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of tartaric acid functional compds. for the treatment of inflammatory disorders)

RN 871713-82-5 CAPLUS

CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-chlorophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-83-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[(5-phenyl-2-pyridinyl)methyl]-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-84-7 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-(2-methoxyphenyl)-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-85-8 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-88-1 CAPLUS
CN 2H-Isoindole-2-butanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-1,3-dihydro-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-89-2 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-90-5 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-2-(2-thiazolyl)-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-91-6 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-2-(4-fluorophenyl)-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-92-7 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[[5-(2-ethoxyphenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-93-8 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-[2-(1-methylethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-94-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[[5-[2-(phenylmethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-95-0 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-cyanophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871713-96-1 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-N-[[5-(2-methoxyphenyl)-2-pyridinyl]methyl]-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871723-96-5 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[1-[5-(2-cyanophenyl)-2-pyridinyl]ethyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871723-99-8 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[1-[5-[2-(aminocarbonyl)phenyl]-2-pyridinyl]ethyl]-2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871724-02-6 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-α,β-dihydroxy-γ-oxo-N-[1-[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]ethyl]-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871724-05-9 CAPLUS
CN 1-Pyrrolidinebutanamide, 2-(3-chlorophenyl)-N-[1-[5-(2-ethoxyphenyl)-2-pyridinyl]ethyl]-α,β-dihydroxy-γ-oxo-, (αR,βR,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-75-5 CAPLUS
CN 2H-Isoindole-2-butanamide, N-[[6-cyano-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-1,3-dihydro-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-76-6 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-N-[[6-methoxy-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-77-7 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-N-[[1-oxido-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-78-8 CAPLUS
CN 2H-Isoindole-2-butanamide, 1,3-dihydro-α,β-dihydroxy-N-[[1-oxido-5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-79-9 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[[5-(2-ethoxy-4-fluorophenyl)-2-pyridinyl]methyl]-α,β-dihydroxy-γ-oxo-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871728-80-2 CAPLUS
CN 1-Pyrrolidinebutanamide, α,β-dihydroxy-γ-oxo-N-[[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871729-25-8 CAPLUS
CN 2-Pyridinepropanamide, α,β-dihydroxy-N-[[5-[2-(trifluoromethoxy)phenyl]-2-pyridinyl]methyl]-, (αR,βS)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:612238 CAPLUS
DOCUMENT NUMBER: 143:133188
TITLE: Preparation of α-hydroxy carboxamides, particularly N-biphenylmethyl and N-phenylpyridin-2-ylmethyl amides, as bradykinin B1

antagonists or inverse agonists useful in the treatment of pain and inflammation

INVENTOR(S): Wood, Michael R.; Anthony, Neville J.; Bock, Mark G.; Kuduk, Scott D.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 51 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063690	A1	20050714	WO 2004-US42691	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309357	A1	20050714	AU 2004-309357	20041217
CA 2550372	A1	20050714	CA 2004-2550372	20041217
CA 2550372	C	20090929		
EP 1706372	A1	20061004	EP 2004-814829	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1898198	A	20070117	CN 2004-80038255	20041217
BR 2004017928	A	20070417	BR 2004-17928	20041217
JP 2007520472	T	20070726	JP 2006-547200	20041217
ZA 2006004398	A	20071227	ZA 2006-4398	20060530
IN 2006DN03156	A	20070824	IN 2006-DN3156	20060602
US 20080318976	A1	20081225	US 2006-583675	20060619
MX 2006007203	A	20060818	MX 2006-7203	20060621
KR 2006115753	A	20061109	KR 2006-712382	20060621
NO 2006003394	A	20060912	NO 2006-3394	20060721

PRIORITY APPLN. INFO.:	US 2003-531643P	P	20031222
	US 2004-539637P	P	20040128
	US 2004-624958P	P	20041104
	WO 2004-US42691	W	20041217

OTHER SOURCE(S): CASREACT 143:133188; MARPAT 143:133188

GI



I



II

AB Title compds. [I; Y = CH, N; R1 = (un)substituted Ph, 2,2-dioxo-2,1-benzisothiazolin-1-yl; R2 = H, (un)substituted alkyl, Ph, etc.; R3 = defined as R2; or R3 = OH; or R2CR3 = (un)substituted 3-7-membered carbocyclyl; R4, R5 = independently H, halo/alkyl; R7 = H, halo] were prepared as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation associated with the bradykinin B1 pathway. For example, coupling of 1-hydroxycyclopropanecarboxylic acid with Me 4'-(aminomethyl)biphenyl-2-carboxylate gave amide II. I have affinity for the B1 receptor in a radioligand assay as demonstrated by results of less than 5 μM [sic].

IT 858412-39-2P, (2R)-N-[(1R)-1-[5-[5-Chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoropyridin-2-yl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methylpropanamide 858412-96-1P
858412-97-2P 858412-98-3P 858412-99-4P
858413-00-0P 858413-01-1P 858413-05-5P
858413-08-8P 858413-13-5P 858413-14-6P
858413-15-7P 858413-16-8P 858413-22-6P
858413-23-7P 858413-24-8P 858413-25-9P
858413-26-0P 858413-32-8P 858413-33-9P
858413-34-0P 858413-35-1P 858413-36-2P
858413-37-3P 858413-38-4P 858413-39-5P
858413-40-8P 858413-41-9P 858413-43-1P
858413-45-3P 858413-46-4P 858413-47-5P
858413-48-6P 858413-49-7P 858413-50-0P
858413-52-2P 858413-53-3P 858413-54-4P
858413-56-6P 858413-57-7P 858413-59-9P
858413-60-2P 858413-61-3P 858413-62-4P
858413-63-5P 858413-64-6P 858413-68-0P
858413-69-1P 858413-70-4P 858413-72-6P
858413-73-7P 858413-78-2P 858413-79-3P
858413-80-6P 858413-81-7P 858413-82-8P
858413-85-1P 858413-86-2P 858413-92-0P
858413-94-2P 858413-95-3P 858413-96-4P
858413-98-6P 858413-99-7P 858414-00-3P
858414-01-4P 858414-02-5P 858414-03-6P
858414-04-7P 858414-06-9P 858414-07-0P
858414-08-1P 858414-09-2P 858414-10-5P
858414-11-6P 858414-12-7P 858414-13-8P
858414-14-9P 858414-15-0P 858414-16-1P
858414-17-2P 858414-18-3P 858414-27-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of N-biphenylmethyl and N-phenylpyridin-2-ylmethyl α-hydroxycarboxamides as bradykinin B1 antagonists or inverse agonists useful in the treatment of pain and inflammation)

RN 858412-39-2 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858412-96-1 CAPLUS
CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858412-97-2 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858412-98-3 CAPLUS
CN Benzoic acid, 4-chloro-2-fluoro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858412-99-4 CAPLUS
CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-00-0 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2-difluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-01-1 CAPLUS
CN Propanamide, N-[(1R)-1-[5-(3,5-dichloro-2-ethoxyphenyl)-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-05-5 CAPLUS
CN Propanamide, N-[(1R)-1-[5-(3,5-dichloro-2-cyanophenyl)-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-08-8 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-13-5 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-14-6 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-15-7 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(1-methylethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-16-8 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-22-6 CAPLUS
CN Benzamide, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-23-7 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-2-(ethylthio)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-24-8 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2,2,2-trifluoroethoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-25-9 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-26-0 CAPLUS
CN Benzoic acid, 2-[5-chloro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-6-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-32-8 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-33-9 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-2-(2,2-difluoroethoxy)-3-fluorophenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-34-0 CAPLUS
CN Benzoic acid, 2,4-dichloro-6-[5-chloro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-35-1 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(2-methylpropoxy)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-36-2 CAPLUS
CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-37-3 CAPLUS
CN Benzoic acid, 2,4-dichloro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-38-4 CAPLUS
CN Benzoic acid, 2-chloro-6-[5-fluoro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-39-5 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-40-8 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-2-(ethylsulfinyl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-41-9 CAPLUS
CN Benzoic acid, 2-chloro-6-[5-chloro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-43-1 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-2-hydroxy-2-methyl-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 858413-45-3 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-46-4 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-47-5 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-48-6 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-[(1R)-1-[3-fluoro-5-[3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]ethyl]-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-49-7 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-50-0 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[5-chloro-3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-52-2 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-53-3 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-54-4 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3-chloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-56-6 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-57-7 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-59-9 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-60-2 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-5-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-61-3 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-5-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-62-4 CAPLUS
CN Benzoic acid, 2,4-dichloro-6-[5-chloro-6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-63-5 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-64-6 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-68-0 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-difluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-69-1 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-difluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-70-4 CAPLUS
CN Benzoic acid, 2,4-dichloro-6-[6-[(1R)-1-[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]ethyl]-3-pyridinyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-72-6 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3-chloro-5-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-73-7 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3-chloro-5-methyl-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-78-2 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-difluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-79-3 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3,5-difluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-80-6 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3,5-difluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-81-7 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-2-(ethylsulfonyl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-82-8 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3,5-dichloro-2-[5-(1-methylethyl)-1,2,4-oxadiazol-3-yl]phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-85-1 CAPLUS
CN Propanamide, N-[(1R)-1-[5-[3-chloro-5-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-86-2 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3,5-difluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-92-0 CAPLUS
CN Benzoic acid, 2-[5-chloro-6-[[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-94-2 CAPLUS
CN Propanamide, N-[[5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-95-3 CAPLUS
CN Propanamide, N-[[5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-96-4 CAPLUS
CN Propanamide, N-[[3-chloro-5-[5-chloro-3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-98-6 CAPLUS
CN Propanamide, N-[[3-chloro-5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858413-99-7 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3,5-dichloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-00-3 CAPLUS
CN Propanamide, N-[[3-chloro-5-[5-chloro-3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-01-4 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-02-5 CAPLUS
CN Propanamide, N-[[5-[3,5-difluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-03-6 CAPLUS
CN Propanamide, N-[[5-[5-chloro-3-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-04-7 CAPLUS
CN Propanamide, 3,3,3-trifluoro-N-[[3-fluoro-5-[3-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-06-9 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3,5-difluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-07-0 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3-chloro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-08-1 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3,5-dichloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 858414-09-2 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3,5-difluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 858414-10-5 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3,5-difluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 858414-11-6 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3-chloro-5-fluoro-2-(2-methyl-2H-tetrazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 858414-12-7 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3-chloro-5-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-13-8 CAPLUS
CN Benzoic acid, 4-chloro-2-[5-chloro-6-[[[(2R)-3,3,3-trifluoro-2-hydroxy-2-methyl-1-oxopropyl]amino]methyl]-3-pyridinyl]-6-fluoro-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-14-9 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-15-0 CAPLUS
CN Propanamide, N-[[5-[3,5-dichloro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-16-1 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3-chloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-17-2 CAPLUS
CN Propanamide, N-[[3-chloro-5-[3-chloro-5-fluoro-2-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-18-3 CAPLUS
CN Propanamide, N-[[5-[5-chloro-3-fluoro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-3-fluoro-2-pyridinyl]methyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 858414-27-4 CAPLUS
CN Propanamide, N-[(1R)-1-[3-chloro-5-[3,5-dichloro-2-(3-methyl-1,2,4-oxadiazol-5-yl)phenyl]-2-pyridinyl]ethyl]-3,3,3-trifluoro-2-hydroxy-2-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT:	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>